Cell surface-directed therapy |
Anti-CD3 mAb, anti-CD4 mAb, anti-CD5 mAb, anti-CD7 mAb, anti-CD20 mAb (rituximab), anti-CD25 mAb, anti-CD28 mAb, anti-CD52 mAb, IL2 fusion protein, anti-ICAM-1, CTLA-4-Ig (CD86 binding) |
Cytokine targeted therapy |
TNF antagonists (mAb, soluble TNF receptor) |
IL1 receptor antagonist |
IL6 antagonist (mAb against IL6 or IL6 receptor) |
Administration of cytokines (IL4, IL10, IFNγ, and IFNβ) |
Tolerance induction |
Application of antigens (collagen II, HCGP-39) |
T cell or T cell receptor vaccination |
Interference with T cell activation (CTLA-4-Ig) |
Inhibition of chemokines |
Inhibition of complement activation |
High dose intravenous immunoglobulins |
Plasmapheresis, immunoadsorption column |
Autologous bone marrow transplantation |